Fuchs' Endothelial Dystrophy Clinical Trial
Official title:
Phase 1 Clinical Study to Evaluate Safety and Tolerability of Magnetic Human Corneal Endothelial Cells in the Treatment of Corneal Edema
Single center, phase 1 study to evaluate the safety and tolerability of EO1404 in subjects with corneal edema secondary to pseudophakic bullous keratopathy or Fuch's endothelial dystrophy.
Status | Recruiting |
Enrollment | 35 |
Est. completion date | February 28, 2021 |
Est. primary completion date | December 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility |
Inclusion Criteria: 1. Age = 21 years 2. Pseudophakic with a posterior chamber intraocular lens. 3. Symptomatic corneal edema associated with endothelial dysfunction which may be secondary to Fuchs corneal dystrophy or pseudophakic bullous keratopathy. a Symptoms including reduced vision and/or glare, and/or pain; subject may or may not have been on topical therapies such as 5% sodium chloride drops or prednisolone acetate 1% drops. b ETDRS-best corrected visual acuity worse than 20/63 on Snellen. c Central corneal thickness < 2 mm by ultrasound pachymetry or OCT. d Subject must have progressed far enough in their clinical course to be considered a surgical candidate for full-thickness corneal transplantation or endothelial keratoplasty. 4. Subject must understand and sign the informed consent. If the subject's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the subject in their maternal language. 5. Subject must be medically able and willing to undergo the protocol-required procedures. Exclusion Criteria: All ocular criteria apply to study eye unless otherwise noted. 1. Other corneal disease, including active or prior herpetic ocular infection; active inflammation; corneal scarring from trauma, burns, or infection; or band keratopathy. 2. Visual acuity in the fellow eye is worse than 20/200. 3. Anterior chamber intraocular lens. 4. Subject requires topical, intravenous or oral acyclovir and/or related products during study duration 5. History of vitrectomy. 6. History of refractive surgery. 7. Macular disease that in the investigator and/or sponsor's opinion would limit the ability of the subject to demonstrate improvement in BCVA. 8. Prior incisional eye surgery within 3 months prior to study treatment. 9. Subject is receiving systemic steroids or other systemic immunosuppressive medications. 10. Subject is currently participating in or has participated within the last 3 months in any other clinical trial of an investigational drug by ocular or systemic administration. 11. History of uveitis or other ocular inflammatory disease. 12. History of glaucoma, or peripheral anterior synechiae on gonioscopy. 13. History of incisional glaucoma surgery (e.g., trabeculectomy, glaucoma drainage implant). 14. Female subject who is pregnant, nursing, or planning to become pregnant, or who is of childbearing potential and not using a reliable means of contraception during the study. 15. Subject is immunodeficient, or tested positive for HIV. 16. Subject is on chemotherapy. 17. History of malignancy other than basal cell carcinoma, UNLESS the malignancy was treated successfully 5 years prior to inclusion in the study. 18. History of ocular neoplasm. |
Country | Name | City | State |
---|---|---|---|
Mexico | Asociación Para Evitar la Ceguera en México, IAP, Hospital "Dr. Luis Sánchez Bulnes" | Mexico City |
Lead Sponsor | Collaborator |
---|---|
Valeria Sanchez-Huerta | Emmecell |
Mexico,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluation of Adverse Events | Evaluation of safety adverse events including worsening of corneal edema and increase in intraocular pressure | 12 months | |
Secondary | BVCA | Best corrected visual acuity | 12 months | |
Secondary | Corneal thickness | Decrease in corneal thickness | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03248037 -
Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation
|
Phase 3 | |
Recruiting |
NCT03275896 -
Evaluation of the Efficacy of Descemet Membrane Transplantation for the Treatment of Fuchs' Endothelial Dystrophy
|
Early Phase 1 | |
Completed |
NCT02332109 -
ODM 5 in the Treatment of Corneal Edematous Fuchs' Endothelial Dystrophy
|
N/A | |
Completed |
NCT02470793 -
Technique And Results In Endothelial Keratoplasty
|
N/A | |
Recruiting |
NCT01206127 -
DSAEK- Postoperative Positioning and Transplant Dislocation
|
N/A | |
Recruiting |
NCT03407755 -
Air Versus SF6 for Descemet's Membrane Endothelial Keratoplasty (DMEK)
|
N/A | |
Completed |
NCT04140422 -
Eye Drops for Early Morning-Associated Corneal Swelling of the Cornea
|
N/A | |
Recruiting |
NCT06048380 -
The Effects of Ripasudil in Patients With FED Undergoing Femtosecond Laser Assisted Cataract Surgery
|
Phase 3 | |
Completed |
NCT02793310 -
DMEK Versus DSAEK Study
|
N/A | |
Completed |
NCT01795001 -
The Molecular Pathogenesis of Late-onset Fuchs' Endothelial Corneal Dystrophy
|
||
Completed |
NCT04057053 -
Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty
|
Early Phase 1 | |
Terminated |
NCT01361282 -
Using the Optovue OCT to Select IOL Power
|
N/A | |
Completed |
NCT02542644 -
Assessment of Corneal Graft Attachment in Patients With Fuchs Endothelial Corneal Dystrophy Following DMEK Using Ultra-high Resolution OCT
|
N/A | |
Completed |
NCT05399095 -
Supine Positioning for Graft Attachment After Descemet Membrane Endothelial Keratoplasty
|
N/A | |
Completed |
NCT04752020 -
Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty
|
Early Phase 1 | |
Not yet recruiting |
NCT05716945 -
The OPTIMISE Study
|
Phase 4 | |
Recruiting |
NCT03575130 -
Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal Dystrophy
|
Phase 2 | |
Recruiting |
NCT02118922 -
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
|
||
Completed |
NCT04420429 -
The Effect Of Preoperative Parameters On Success After DMEK Surgery
|
||
Withdrawn |
NCT04018417 -
Evaluation of Amphotericin B in Optisol-GS for Prevention of Post-Keratoplasty Fungal Infections.
|
Phase 2/Phase 3 |